Roxadustat improves CVD outcomes in anaemic patients with CKD

Roxadustat improves CVD outcomes in anaemic patients with CKD

Roxadustat lowered the adverse cardiovascular events in chronic kidney disease (CKD) patients with anaemia, according to data recently presented at American Society of Nephrology (ASN) Kidney Week.

According to the findings from the post-hoc analyses from roxadustat global phase 3 programme the patients who were treated with roxadustat showed lowest rates of cardiovascular events and their haemoglobin levels were maintained at or above 10 g/dL, said the researchers.

Overall, 2,391 patients received roxadustat in the non-dialysis dependent (NDD) cohort, and 1,943 patients were randomized to receive roxadustat in the dialysis-dependent (DD) trial. Mean haemoglobin was 9.63 g/dL at baseline in the DD group, and 9.1 g/dL at baseline for patients in the NDD group.

In the DD and NDD patient population, the occurrence of major adverse cardiovascular events (MACE) and MACE+ (MACE plus heart failure or unstable angina requiring hospitalization) were lowest when achieved haemoglobin levels at more than or equal to 11g/dL. Patients with haemoglobin less than 8 g/dL in both categories faced a higher risk of adverse events, but MACE decreased as haemoglobin increased.